

**Supplementary. Table 1:** Patient/transplant characteristics across Apolipoproteins B/A1 quartiles, 2010-2015

Characteristic	Q1, N=135	Q2, N=136	Q3, N=137	Q4, N=137	R <sup>2</sup>	P
Patient count, f/u time (p-y)	135, 315.0	136, 303.9	137, 320.6	137, 301.7	---	---
Apolipoprotein B/A1 ratio	0.4±0.1	0.5±0.0	0.6±0.0	0.8±0.2	---	---
Apolipoprotein A1 (g/L)	1.8±0.3	1.6±0.3	1.5±0.3	1.3±0.2	0.293	<0.001
Apolipoprotein B (g/L)	0.6±0.1	0.7±0.1	0.9±0.2	1.0±0.2	0.619	<0.001
<b>Demography/Allograft Data</b>						
Age at bloodwork (years)	53.1±12.8	54.3±12.9	53.9±13.9	53.1±13.2	-0.001	0.694
Age at transplant (years)	52.7±12.9	53.7±13.0	53.4±13.9	52.7±13.3	-0.001	0.629
>2 transplants	7, 2.5%	10, 3.6%	10, 3.6%	11, 4.0%	---	---
Live donor	50, 18.1%	59, 21.4%	49, 17.8%	45, 16.3%	---	---
Male	66, 23.9%	79, 28.6%	85, 30.8%	96, 34.8%	---	---
Ethnicity	53, 19.2%	41, 14.9%	49, 17.8%	47, 17.0%	---	---
<b>ESRD Cause</b>						
Hypertension	12, 4.35%	24, 8.7%	23, 8.33%	14, 5.0%	---	---
Glomerulonephritis	43, 15.6%	44, 15.9%	42, 15.2%	50, 18.1%	---	---
Polycystic Kidney Disease	18, 6.5%	19, 6.9%	18, 6.52%	27, 9.8%	---	---
<b>Clinical Characteristics</b>						
Height (cm)	166.8±30.2	168.3±29.7	170.1±22.8	169.7±33.4	0.006	0.048*
Weight (kg)	70.6±17.0	71.3±15.9	74.8±16.3	75.5±15.6	0.008	0.018*
Body-mass index (kg/m <sup>2</sup> )	25.3±4.7	25.1±4.8	25.6±4.5	26.2±4.8	0.004	0.082
Systolic BP (mmHg)	129.8±15.5	129.7±14.4	128.5±17.4	129.7±15.4	0.000	0.385
Diastolic BP (mmHg)	81.2±9.5	81.6±10.2	81.2±10.2	82.3±10.3	0.000	0.494
Waist circumference (cm)	89.1±16.1	90.0±20.2	94.0±14.3	95.3±20.5	0.022	0.005
Hip circumference (cm)	94.9±13.6	95.0±19.3	97.8±11.8	98.4±19.4	0.039	0.039
Waist-to-hip ratio	0.94±0.08	0.95±0.16	0.96±0.08	0.97±0.18	0.027	<0.001
<b>Laboratory Measurements</b>						
Fasting blood glucose	5.6±2.1	5.7±1.7	5.9±2.4	6.1±1.8	0.013	0.004
Random blood glucose	6.1±2.4	6.1±2.3	6.5±3.2	6.8±2.5	0.008	0.018*
HbA1c	5.5±1.0	5.6±0.8	5.6±1.0	5.8±1.1	0.015	0.002
Total cholesterol	4.2±1.2	4.6±1.3	4.6±1.2	5.2±1.42	0.147	<0.001
HDL-cholesterol	1.7±0.6	1.4±0.5	1.3±0.4	1.1±0.4	0.211	<0.001
LDL-cholesterol	2.0±0.9	2.3±1.0	2.5±1.1	3.2±1.4	0.289	<0.001
HDL/LDL ratio	1.2±0.6	1.7±0.7	2.0±0.8	3.0±1.4	0.610	<0.001
Triglycerides	1.4±1.08	1.6±0.8	1.9±0.8	2.4±1.3	0.157	<0.001
Non-HDL cholesterol	2.6±0.9	3.03±1.0	3.3±0.9	4.1±1.3	0.377	<0.001
Total cholesterol/HDL ratio	2.8±0.9	3.2±0.9	3.8±0.9	5.3±3.8	0.318	<0.001
C-reactive protein (mg/L)	3.4±9.7	3.5±5.2	4.8±8.0	10.5±26.9	0.004	<0.001
Parathyroid hormone (pmol/L)	14.0±16.1	15.0±16.8	13.8±11.9	18.5±20.0	0.006	0.035
Vitamin D25 (nmol/L)	49.0±27.5	50.8±25.5	47.3±24.3	42.6±26.1	0.013	0.005
Uric Acid (μmol/L)	348.4±102.	347.7±93.5	369.6±92.2	390.3±111.	0.035	<0.001
24h urine protein (g/d)	0.7±0.36	0.8±0.5	0.7±0.4	1.1±0.5	-0.009	0.623
<b>Renal Function/Outcomes</b>						
Serum creatinine (μmol/L)	120.7±56.5	116.3±35.5	127.4±50.2	136.8±90.9	0.015	0.003
Estimated GFR (ml/min/1.73m <sup>2</sup> )	56.8±19.8	57.1±17.6	53.7±18.5	54.9±19.9	0.006	0.044
Urine ACR (mg/mmol)	7.1±13.2	8.4±40.2	8.2±15.3	12.1±24.9	0.002	0.126
Graft failure	12, 4.4%	9, 3.3%	14, 5.1%	10, 3.6%	---	0.895
Metabolic syndrome	95, 34.4%	83, 30.1%	92, 33.3%	96, 34.8%	---	0.363
Acute rejection	8, 2.9%	6, 2.2%	11, 4.0%	8, 2.9%	---	0.343

Delayed graft function	5, 1.8%	2, 0.7%	8, 2.9%	4, 1.5%	---	0.984
<b>Medications</b>						
Statin	76, 27.5%	63, 22.8%	58, 21.0%	37, 13.4%	---	0.298
Cyclosporine	6, 2.2%	9, 3.3%	13, 4.7%	17, 6.2%	---	0.686
Tacrolimus	127, 46.0%	122, 44.2%	116, 42.0%	114, 41.3%	---	0.793
Mycophenolate mofetil	76, 27.5%	72, 26.1%	67, 24.3%	73, 26.5%	---	0.317
Mycophenolic acid	44, 15.9%	46, 16.7%	52, 18.8%	53, 19.2%	---	0.102

R statistic not provided for binary characteristics, as logistic regression was used for these characteristics instead of linear regression. Laboratory measurements with unlisted units are mmol/L. Binary factors expressed in (number (N), %) unless otherwise specified. Abbreviations: ACR albumin-to-creatinine ratio, ESRD end-stage renal disease, GFR glomerular filtration rate, HbA1c glycated hemoglobin, HDL high density lipoprotein, LDL low density lipoprotein, p-y patient years

**Supplementary Table 2:** Differences in clinical characteristics between incident PTDM and non-PTDM cases, 2010-2015.

<b>Variable</b>	<b>PTDM (29)</b>	<b>No PTDM (516)</b>	<b>P</b>
Apo A1 (g/L)	1.55±0.30	1.52±0.79	0.838
Apo B (g/L)	0.96±0.30	0.81±0.23	<0.001
Apo B/A1 ratio	0.64±0.25	0.55±0.31	0.128
Graft failure	2, 6.9%	43, 8.3%	0.786
Serum creatinine (mmol/mL)	117.1±34.6	125.8±76.6	0.607
eGFR (ml/min/1.73m <sup>2</sup> )	57.4±20.6	55.5±30.7	0.745
FBS (mmol/L)	7.3±2.3	5.7±3.15	0.007
RBS (mmol/L)	8.1±4.1	6.3±3.56	<0.001
Cyclosporine	4, 13.8%	41, 8.0%	0.267
Tacrolimus	24, 82.8%	455, 88.2%	0.384
Statin	25, 86.2%	341, 66.1%	0.025

Significance assessed using comparison of incidence rates, Student's t-test, or fisher exact test, as appropriate.